Assessing the Safety and Therapeutic Efficacy of Cannabidiol Lipid Nanoparticles in Alleviating Metabolic and Memory Impairments and Hippocampal Histopathological Changes in Diabetic Parkinson's Rats

Diabetic Parkinson's disease (DP) is a progressive neurodegenerative disease with metabolic syndrome that is increasing worldwide. Emerging research suggests that cannabidiol (CBD) is a neuropharmacological compound that acts against this disease, especially CBD in nano-formulation. The safety...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2024-04, Vol.16 (4), p.514
Main Authors: Lapmanee, Sarawut, Bhubhanil, Sakkarin, Wongchitrat, Prapimpun, Charoenphon, Natthawut, Inchan, Anjaree, Ngernsutivorakul, Thitaphat, Dechbumroong, Piroonrat, Khongkow, Mattaka, Namdee, Katawut
Format: Article
Language:English
Subjects:
Animals
Bioavailability
Brain
Cannabidiol
Cytotoxicity
Diabetes
Diet
Dopa
Dopamine
drug delivery
Ethanol
Glucose
Health aspects
lipid nanoparticles
Lipids
Memory
Metabolism
Nanoparticles
Neurons
Parkinson’s disease
Solvents
Type 2 diabetes
type 2 DM
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetic Parkinson's disease (DP) is a progressive neurodegenerative disease with metabolic syndrome that is increasing worldwide. Emerging research suggests that cannabidiol (CBD) is a neuropharmacological compound that acts against this disease, especially CBD in nano-formulation. The safety of cannabidiol lipid nanoparticles (CBD-LNP) was evaluated by assessing in vitro cytotoxicity in neurons and therapeutic outcomes in a DP animal model, including metabolic parameters and histopathology. CBD-LNPs were fabricated by using a microfluidization technique and showed significantly lower cytotoxicity than the natural form of CBD. The DP rats were induced by streptozotocin followed by a 4-week injection of MPTP with a high-fat diet. Rats were treated orally with a vehicle, CBD, CBD-LNP, or levodopa for 4 weeks daily. As a result, vehicle-treated rats exhibited metabolic abnormalities, decreased striatal dopamine levels, and motor and memory deficits. CBD-LNP demonstrated reduced lipid profiles, enhanced insulin secretion, and restored dopamine levels compared to CBD in the natural form. CBD-LNP also had comparable efficacy to levodopa in ameliorating motor deficits and memory impairment in behavior tests. Interestingly, CBD-LNP presented migration of damaged neuronal cells in the hippocampus more than levodopa. These findings suggest that CBD-LNP holds promise as an intervention addressing both metabolic and neurodegenerative aspects of DP, offering a potential therapeutic strategy.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics16040514